<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482507</url>
  </required_header>
  <id_info>
    <org_study_id>IMM 10-0120 (DWI101)</org_study_id>
    <nct_id>NCT01482507</nct_id>
  </id_info>
  <brief_title>Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimus Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthritis Australia, Abbott Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Optimus Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diffusion Weighted Imaging (DWI) MRI will assist in differentiating poor prognosis bone&#xD;
      oedema more effectively than traditional T2 weighted MRI in patients with early Rheumatoid&#xD;
      Arthritis (RA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess DWI MRI in patients with early Rheumatoid Arthritis to determine whether the MRI&#xD;
      method will assist in differentiating poor prognosis bone oedema more effectively than&#xD;
      traditional T2 weighted MRI.&#xD;
&#xD;
      Aim 1: To compare DWI MRI with T2 weighted MRI for the discrimination of different types of&#xD;
      bone oedema lesions in patients with early RA.&#xD;
&#xD;
      Aim 2: To examine the association between the presence of different types of bone oedema&#xD;
      lesions detected on DWI MRI and T2 weighted MRI and the development of subsequent joint bone&#xD;
      erosion as detected on i) MRI and ii) standard plain radiographs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">10</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed Patients with active Rheumatoid Arthritis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has Rheumatoid Arthritis as defined by the ACR/Eular criteria&#xD;
&#xD;
          -  Subject is able to understand and comply with study protocol&#xD;
&#xD;
          -  Active disease as defined by DAS28&gt; 3.0&#xD;
&#xD;
          -  Disease duration less than 12 months&#xD;
&#xD;
          -  If female, subject is either not of childbearing potential, or is of childbearing&#xD;
             potential and is practicing an approved method of birth control throughout the study&#xD;
&#xD;
          -  subject is judged to be in good health as determined by the PI based upon results of&#xD;
             medical history, laboratory profile and physical examination.&#xD;
&#xD;
          -  Prednisone dose 10mg or less, dose stable for 28 days prior to baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory arthropathy other than Rheumatoid Arthritis&#xD;
&#xD;
          -  Inactive disease as evidenced by DAS 28 CRP and / or ESR &lt; 2.5&#xD;
&#xD;
          -  Prednisone dose greater than 10mg within 28 days prior to baseline&#xD;
&#xD;
          -  Intra-articular steroid within 28 days prior to baseline visit&#xD;
&#xD;
          -  IV Methyl-prednisone within 28 days prior to baseline visit&#xD;
&#xD;
          -  Any contra-indication to Magnetic Resonance Imaging&#xD;
&#xD;
          -  Permanent Pacemaker&#xD;
&#xD;
          -  Intracerebral aneurysm clip&#xD;
&#xD;
          -  Claustrophobia to the extent that patient cannot manage MRI investigations&#xD;
&#xD;
          -  Implanted metallic device&#xD;
&#xD;
          -  Cochlear implant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Bird, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optimus Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimus Clinical Research</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>November 27, 2011</study_first_submitted>
  <study_first_submitted_qc>November 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Optimus Clinical Research</investigator_affiliation>
    <investigator_full_name>Paul Bird</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

